Every Form 4 that MoonLake Immunotherapeutics (MLTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MLTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MLTX filings page.
Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, reported the sale of 1,100 Class A ordinary shares at $20.00 per share on July 27, 2026. The shares were owned by JeruCON Beratungsgesellschaft mbH and sold under a Rule 10b5-1 trading plan adopted March 10, 2026. After the transaction, Dr. Reich reported indirect beneficial ownership of 2,711,198 shares through JeruCON and direct ownership of 35,389 shares.
MoonLake Immunotherapeutics reported that JeruCON Beratungsgesellschaft mbH, an entity associated with Chief Scientific Officer Kristian Reich, sold 50,000 and 2,448 Class A ordinary shares on July 21–22, 2026. The 50,000-share block was sold at a weighted average price of $20.0200 per share, in trades between $20.00 and $20.06, and the 2,448-share block at $20.00 per share. Both sales were executed pursuant to a Rule 10b5-1 trading plan adopted March 10, 2026.
Reich may be deemed the indirect beneficial owner of JeruCON’s shares and directly held 35,389 Class A ordinary shares as of July 21, 2026.
MoonLake Immunotherapeutics Chief Scientific Officer Kristian Reich reported that JeruCON Beratungsgesellschaft mbH, an entity whose holdings he may be deemed to beneficially own, sold 43,700 Class A ordinary shares on July 20, 2026 at a weighted average price of $20.09 per share under a Rule 10b5-1 trading plan adopted on March 10, 2026. After the sale, JeruCON held 2,764,746 shares indirectly attributable to him, and he also held 35,389 shares directly.
MoonLake Immunotherapeutics Chief Scientific Officer Kristian Reich reported an indirect sale by JeruCON Beratungsgesellschaft mbH of 16,105 Class A shares on July 15, 2026 under a Rule 10b5-1 trading plan adopted March 10, 2026 at a weighted average price of $20.01 per share, with individual trades from $20.00 to $20.04.
After the sale, JeruCON remained the indirect holder of 2,808,446 Class A ordinary shares, while Reich directly held 35,389 Class A shares.
MoonLake Immunotherapeutics Chief Executive Officer Jorge Santos da Silva reported open‑market sales of Class A ordinary shares. On July 9 and 10, 2026, he sold a total of 102,225 shares at weighted average prices around $20.01–$20.02 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on March 31, 2026.
Following these transactions, he directly holds 2,774,893 Class A ordinary shares. The reported prices reflect weighted averages across multiple trades within narrow intraday ranges, with detailed per‑trade information available upon request from the issuer, the SEC staff, or a security holder.
MoonLake Immunotherapeutics director and Chief Executive Officer Jorge Santos da Silva sold 47,775 Class A ordinary shares in an open-market transaction at a weighted average price of $20.03 per share. The sale was executed on July 1, 2026 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2026.
Following this transaction, he directly holds 2,877,118 Class A ordinary shares. The filing notes that the reported price reflects a weighted average across multiple individual trades executed between $20.00 and $20.09 per share.
MoonLake Immunotherapeutics’ Chief Financial Officer Matthias Bodenstedt reported an open-market sale of 39,120 Class A ordinary shares on June 22, 2026. The shares were sold at a weighted average price of $22.04 per share, in multiple trades between $19.87 and $23.2049. Following the sale, he directly holds 1,115,435 shares, so the transaction represents a small portion of his stake. The sale was executed under a pre-arranged Rule 10b5‑1 trading plan adopted on December 10, 2025, indicating it was scheduled in advance.
MoonLake Immunotherapeutics received an updated ownership report from a group of BVF-related investment funds and Mark N. Lampert, who together form a Section 13(d) group holding more than 10% of the company’s common stock. The filing mainly records existing Class A Ordinary Share positions and a new stock option award linked to director Spike Loy’s service. The option covers 22,195 Class A Ordinary Shares at an exercise price of $19.19 per share, expiring on June 17, 2036, and vests in full on the earlier of June 17, 2027 or the next annual general meeting of shareholders, subject to his continued service. The group and Mr. Loy each disclaim beneficial ownership beyond their economic interests.
MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt reported open-market sales of 17,876 Class A ordinary shares. The shares were sold on two days at weighted average prices of about $19.60 and $19.68 per share under a Rule 10b5-1 trading plan adopted on December 10, 2025. Following these transactions, he continues to hold 1,154,555 shares directly.
MoonLake Immunotherapeutics director Andrew John Phillips received a grant of stock options covering 22,195 shares. These options have an exercise price of $19.19 per share and relate to Class A ordinary shares.
The options vest in full on the earlier of June 17, 2027 or the date of MoonLake’s next annual general meeting of shareholders, as long as he continues serving the company. After this grant, the filing shows 22,195 options held directly.
MoonLake Immunotherapeutics director Loy Spike received a compensation-related stock option grant. The award covers 22,195 options to buy Class A ordinary shares at an exercise price of $19.19 per share, with no cash paid for the grant itself.
The option vests in full on the earlier of June 17, 2027 or the company’s next annual general meeting of shareholders, as long as Spike continues to serve the company. The option expires on June 17, 2036 if not exercised.
MoonLake Immunotherapeutics director Catherine Moukheibir received a grant of options to buy 22,195 Class A ordinary shares. The options have an exercise price of $19.19 per share and expire on June 17, 2036. All 22,195 options are shown as held directly after the transaction.
According to the terms, the options will vest in full on the earlier of June 17, 2027 or the date of MoonLake’s next annual general meeting of shareholders, as long as she continues to serve the company.
MoonLake Immunotherapeutics director Xavier Ramnik received a grant of stock options covering 22,195 Class A ordinary shares. The options have an exercise price of $19.19 per share and expire on June 17, 2036.
The option grant vests in full on the earlier of June 17, 2027 or the date of MoonLake’s next annual general meeting of shareholders, subject to Ramnik’s continued service. After this grant, he holds options for 22,195 shares.
MoonLake Immunotherapeutics Chief Scientific Officer Kristian Reich reported open-market sales of a total of 150,000 Class A ordinary shares associated with him over three days. The shares are owned by JeruCON Beratungsgesellschaft mbH, where he is deemed an indirect beneficial owner.
The indirect holdings sold were 50,000 shares on each of June 15, 16, and 17, 2026, at weighted average prices of about $18.89, $18.70, and $19.43 per share, within price ranges from roughly $18.24 to $19.97. These transactions were carried out under a Rule 10b5-1 trading plan adopted on March 10, 2026.
After these sales, JeruCON’s indirect position is reported as 2,824,551 shares, while Reich also holds 35,389 shares directly, indicating that he retains a substantial equity interest in MoonLake Immunotherapeutics following the transactions.
MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt sold 13,653 Class A ordinary shares in an open-market transaction. The shares were sold at a weighted average price of about $20.02 per share across multiple trades between $19.50 and $20.83. After this sale, he directly holds 1,172,431 Class A ordinary shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating it was scheduled in advance rather than timed opportunistically.
MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt sold 2,426 Class A ordinary shares in an open-market transaction. The shares were sold on April 14, 2026 at a weighted average price of $19.56 per share, in multiple trades between $19.50 and $19.625.
After this transaction, he directly holds 1,186,084 Class A ordinary shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating it was scheduled in advance rather than timed discretionarily.
MoonLake Immunotherapeutics Chief Executive Officer Jorge Santos da Silva reported open-market sales of 150,000 Class A ordinary shares of the company. The transactions occurred on April 10 and April 13 at weighted average prices of $18.41 and $18.23 per share, respectively, in multiple trades within disclosed price ranges. Following these sales, he continues to hold 2,924,893 Class A ordinary shares directly. The sales were made pursuant to Rule 144 under the Securities Act, indicating resales of already-owned shares under an established exemption.
MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt reported open-market sales of Class A ordinary shares under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025 to cover his tax liabilities.
He sold 85,870 shares on April 9, 2026 at a weighted average price of $18.94 per share and 1,925 shares on April 10, 2026 at a weighted average price of $19.51 per share, for total reported sales of 87,795 shares. Following these transactions, he directly holds 1,188,510 Class A ordinary shares.
MoonLake Immunotherapeutics’ major shareholder group affiliated with BVF Partners reported substantial open-market sales of Class A Ordinary Shares. On March 31, 2026, the reporting entities sold a combined 3,750,000 shares at $16.79 per share in multiple transactions.
The filing is made jointly by several funds and entities in a Section 13(d) group that collectively owns more than 10% of MoonLake’s common stock, each disclaiming beneficial ownership beyond its pecuniary interest. After these sales, individual reporting entities still report multi‑million share holdings.
The group also reports indirect holdings of three “Option to Buy” awards over 6,682, 7,688 and 11,297 Class A Ordinary Shares with exercise prices of $48.83, $42.44 and $29.18, expiring in 2035, 2034 and 2033 respectively. Two options are fully vested, while the 6,682‑share grant will vest in full by June 5, 2026 or at the next annual general meeting, subject to Spike Loy’s continued service.
MoonLake Immunotherapeutics reported that its Chief Financial Officer, Matthias Bodenstedt, received an award of 354,296 Class A ordinary shares on January 7, 2026. The shares were granted at a price of $0 per share as restricted stock, meaning they are subject to vesting conditions rather than being fully transferable immediately.
According to the filing, these restricted shares will vest in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, as long as he continues to serve the company through each vesting date. After this grant, Bodenstedt beneficially owned a total of 1,276,305 Class A ordinary shares, all held directly.
MoonLake Immunotherapeutics reported that Chief Executive Officer and director Jorge Santos da Silva received a new stock option award. On January 7, 2026, he was granted an option to buy 520,342 Class A ordinary shares at an exercise price of $11.29 per share. The option runs until January 7, 2036.
These options vest over time, rather than all at once. The award vests in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, and each vesting installment requires his continued service with the company through the relevant date. The filing shows he holds these derivative securities directly.
MoonLake Immunotherapeutics reported an equity award to a senior executive. Chief Scientific Officer Kristian Reich filed a Form 4 showing a grant of stock options covering 520,342 Class A ordinary shares at an exercise price of $11.29 per share.
The options were granted on January 7, 2026 and vest in four equal annual installments on January 7, 2027, 2028, 2029, and 2030, as long as he continues to serve the company through each vesting date. Following this grant, he holds 520,342 derivative securities directly.
Insider purchase by MoonLake Immunotherapeutics CFO. The filing shows Matthias Bodenstedt, the company’s Chief Financial Officer and a director, purchased 10,870 Class A ordinary shares on 10/08/2025 at a weighted average price of $9.09 per share. After the transactions he beneficially owns 627,536 shares. The filing notes the shares were bought in multiple trades at prices ranging from $9.085 to $9.091244 and that the weighted average price is reported. The signature date is 10/09/2025.